SCHEDULE 13G/A: BlackRock Discloses 2.2% Stake in THARIMMUNE INC
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 2.2% of THARIMMUNE INC's common stock as of December 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 765,829 shares of THARIMMUNE INC's common stock.
- This represents 2.2% of the total outstanding common stock of THARIMMUNE INC.
- BlackRock, Inc. holds sole voting power and sole dispositive power over all 765,829 shares.
- The filing indicates that these securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of THARIMMUNE INC.
- BlackRock Institutional Trust Company, National Association, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares of THARIMMUNE INC's common stock.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership by an institutional investor. It does not contain information that would inherently drive strong positive or negative sentiment regarding the issuer's performance.
Positives
- Increased institutional investor interest from a major asset manager like BlackRock can signal confidence in the company's long-term prospects.
- The passive nature of the investment (Rule 13d-1(b) filing) suggests BlackRock is not seeking to influence control, which can be viewed as a stable, long-term holding.
Negatives
- The reported 2.2% stake by BlackRock, Inc. (as the parent reporting entity for certain business units) is below the 5% threshold that often triggers more significant market attention for new institutional investments.
Risks
- The filing itself does not detail specific risks related to THARIMMUNE INC's operations or financial health, as it is a disclosure of beneficial ownership.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding THARIMMUNE INC's future performance or strategic direction, as it is a disclosure of beneficial ownership by an institutional investor.
Industry Context
This Schedule 13G filing indicates that BlackRock, a global investment management corporation, holds a passive stake in THARIMMUNE INC. Such filings are routine disclosures by institutional investors when their beneficial ownership in a public company crosses certain thresholds (typically 5%) or when amending previous filings. It reflects BlackRock's investment strategy rather than a direct operational update from THARIMMUNE INC.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, appointing several individuals as attorneys-in-fact for executing and filing ownership or control-person reporting requirements, including Schedules 13D and 13G. This new power of attorney, dated January 21, 2025, expressly revokes a previous one from April 30, 2023. | 2025-01-21 | Streamlines BlackRock's internal processes for regulatory filings, ensuring compliance with reporting requirements across its various subsidiaries and affiliates. |
| Subsidiary Ownership Disclosure | Exhibit 99 identifies BlackRock Institutional Trust Company, National Association as an entity that beneficially owns 5% or greater of the outstanding shares of THARIMMUNE INC's common stock. This clarifies the structure of BlackRock's overall beneficial ownership. | 2025-12-31 | Provides transparency regarding the specific BlackRock entity holding a significant stake, which is relevant for understanding the institutional investor's internal allocation and management of assets. |
Stakeholder Impact
- Shareholders: The disclosure of BlackRock's stake provides transparency regarding institutional ownership, potentially influencing investor sentiment and liquidity.
- Management: Awareness of a significant institutional holder like BlackRock can influence management's strategic decisions and communication with the investment community.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Date of event which requires filing of this statement |
| 2025-01-21 | Date of execution of Power of Attorney by BlackRock, Inc. |
| 2026-01-21 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
THARIMMUNE INC, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.